Refine your search

Content type
Firm name

832 results found

Ask Lexy

Slaughter and May | United Kingdom | 4 Jan 2023

GSK demerger: challenges and opportunities

đź•‘ 2 minutes During Summer 2022, GSK separated its consumer healthcare business (previously a joint venture between GSK and Pfizer) to create the independently UK-listed Haleon group. The demerger fulfilled a key strategic goal for GSK following on from the joint venture with Pfizer and is one of its most significant transactions in the last 20 years, likewise arguably for the UK domestic......
Analysis PRO
Ask Lexy

Lexology PRO | Australia, Canada, China, etc. | 14 Nov 2021

Conference of the Parties 26: what businesses need to know

Key updates from COP26 for the energy, finance, agriculture and transport sectors, including mandatory net-zero plans, rules for fixing methane leaks, and “phasing down” investment in coal.
Analysis PRO
Ask Lexy

Lexology PRO | Asia-Pacific, Australia, Belgium, etc. | 19 May 2021

Competition and antitrust: Key compliance updates (5 – 18 May)

A look at recent enforcement actions against Google, GSK and others, a multi-jurisdictional approach to merger control, new legislation and guidelines in the UK and Canada and other key competition and antitrust updates.
Analysis PRO In-house
Ask Lexy

Lexology PRO | European Union, United Kingdom | 10 May 2021

CAT upholds pay-for-delay decision but trims penalties

The UK’s specialist competition tribunal has confirmed that GlaxoSmithKline and three generic drugmakers broke competition rules by entering into pay-for-delay agreements for the antidepressant drug paroxetine – but slashed the original fines by £27 million.
Ask Lexy

Edgeworth Economics | USA | 24 Jul 2020

Lamictal and the Myth of “Generic” “Pay-for-Delay” Cases

On April 22, 2020, the US Court of Appeals for the Third Circuit overturned a district court decision certifying a class of direct purchaser…
Ask Lexy

Addleshaw Goddard LLP | United Kingdom | 8 Jul 2020

Major success for AG Product Litigation team with indemnity costs award for GSK in long-running Seroxat litigation

On 3 July 2020, Lambert J handed down judgment in the High Court in the Seroxat Group Litigation, bringing to an end 13 years of litigation on the…
Ask Lexy

White & Case | European Union, United Kingdom | 14 Feb 2020

Court of Justice ruling in Paroxetine

The European Court of Justice's ruling in Paroxetine, handed down in record time just before Brexit, confirms the narrow interpretation of…
Ask Lexy

Bereskin & Parr LLP | Canada, USA | 13 Mar 2019

GSK thwarts the attempted “scooping” of its HORLICKS trademark

The Federal Court of Canada has rejected an application by Bedessee Imports Ltd., an importer and distributor of food products, including beverages…
Ask Lexy

Macfarlanes LLP | United Kingdom | 25 Feb 2019

Serious Fraud Office drops two major bribery investigations

The Serious Fraud Office (SFO) has dropped its investigations into individuals at Rolls Royce PLC and GlaxoSmithKline (GSK). The decision to halt two…
Ask Lexy

Gatehouse Chambers | United Kingdom | 3 Jan 2019

ATE and security for costs: Lewis Thermal Limited v Cleveland Cable Company Ltd

This is the third occasion on which I have posted on this blog on the issue of after the event insurance (ATE) policies and the impact which they have…
Previous page 1 2 3 ...